Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirogacestat in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
NCT04195399Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Oct 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of nirogacestat in desmoid fibromatosis (DF), sponsored by Children's Oncology Group. Primary endpoints: Progression-Free Survival at 2 years, Percentage of patients experiencing grade 3+ adverse events at 6 years and 3 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
nirogacestat
03
Conditions
desmoid fibromatosis (DF)
Beyond the preview
Go deeper on NCT04195399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195399.